Where Organ on Chips Will Add the Most Value in 3–5 Years

Why It Matters

A unified, data‑driven CRO for organ‑on‑chip models would streamline drug discovery, cut costs, and accelerate regulatory acceptance, reshaping the biotech landscape.

Key Takeaways

• CROs must scale commercial organ‑on‑chip platforms for broader adoption.
• Startups face budgeting dilemmas between animal studies, NAMs, and organ chips.
• Fragmented CRO market hinders a unified NAM service offering.
• Data sharing across CROs and regulators is essential for field progress.
• Consolidation could create a “Charles River‑type” leader in microphysiological models.

Summary

The discussion centers on how contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) can accelerate the adoption of organ‑on‑chip technologies over the next three to five years. Participants stress that scaling commercial systems and creating a unified service model are critical for moving beyond niche applications.

Key insights include startups wrestling with budget allocations between traditional animal studies, new approach methodologies (NAMs), and costly organ‑chip platforms. A fragmented CRO landscape—featuring specialists like Emulate, CM Bio, and Arkari—lacks a single provider that can meet the full spectrum of NAM needs, prompting calls for consolidation and better integration of computational systems biology with microphysiological models.

Industry voices cite venture‑capital pressure and private‑equity interest in building a dedicated NAM CRO, while established players such as Charles River and Jackson Laboratory are already signaling moves toward these models. A recurring theme is the scarcity of data sharing among CROs and regulators, limiting the FDA’s visibility into emerging pre‑clinical tools.

If a consolidated, data‑rich CRO emerges, it could become the go‑to partner for pharma, reduce reliance on animal testing, and shorten drug‑development timelines, delivering measurable value to investors and patients alike.

Original Description

Panelists emphasized that CROs and CDMOs will be essential to scaling organ on chip adoption, but only if they commit to standardized, commercial execution rather than treating these systems as experimental add ons. As Don Ingber put it plainly, CROs “need to start buying these commercial systems and start scaling” them to make organ on chip studies operationally viable for industry.

Linda Griffith noted that growing interest from biotechs, venture capital, and private equity reflects frustration with the current fragmented NAM landscape. “There’s no one place a company can go to get the NAMs that they need,” she said, pointing to a disconnect between computational NAMs and microphysiological systems. While several companies already operate as specialized organ on chip CROs, Griffith argued the field still lacks a consolidated provider equivalent to established preclinical leaders like Charles River or Jackson Laboratory.

From a regulatory and adoption standpoint, Christine Happle highlighted data sharing as a missing accelerator. Because organ on chip data are often generated in silos, “FDA doesn’t always have information from all of these different sources,” she explained. Encouraging CROs to share data more broadly could help build confidence, support validation, and position CROs not just as service providers, but as key drivers of trust and adoption across the field.

See more at https://www.drugdiscoveryonline.com/